Table 1.
Descriptive characteristics among breast cancer patients by molecular subtypes
| Molecular subtypes | All cases (N = 464)a | Luminal A (N = 228)a | Luminal B (N = 99)a | HER-2 enriched (N = 43)a | TNBC (N = 94)a |
|---|---|---|---|---|---|
| Mean (SD) / % | Mean (SD) / % | Mean (SD) / % | Mean (SD) / % | Mean (SD) / % | |
| Characteristics at study entry | |||||
| Age at blood sampling, years | 39.5 (14.5) | 40.3 (15.2) | 36.5 (10.7) | 41.2 (15.1) | 39.9 (14.7) |
| Age at diagnosis, years | 57.9 (12.6) | 58.8 (12.8) | 57.0 (10.3) | 59.0 (13.3) | 55.9 (13.8) |
| Follow-up after diagnosis, years | 8.43 (6.93) | 9.35 (6.78) | 6.43 (5.59) | 7.27 (6.83) | 8.72 (8.23) |
| Clinical variablesb | |||||
| SBP, mmHg | 125 (19.4) | 125 (19.5) | 123 (15.9) | 129 (24.5) | 126 (20.3) |
| Waist-hip ratio | 0.83 (0.07) | 0.84 (0.08) | 0.81 (0.06) | 0.82 (0.05) | 0.84 (0.07) |
| BMI, kg/m2 | 23.4 (3.68) | 23.3 (3.26) | 23.3 (3.50) | 23.3 (3.86) | 24.1 (4.80) |
| Reproductive factorsb | |||||
| Number of children, number | 1.93 (1.39) | 1.88 (1.33) | 1.63 (1.11) | 2.40 (1.96) | 2.26 (1.53) |
| Age at menarche, years | 13.3 (1.39) | 13.2 (1.50) | 13.4 (1.28) | 13.2 (1.09) | 13.4 (1.30) |
| HRT use, % | 30.5 | 31.5 | 28.7 | 28.6 | 30.5 |
| Serum samplesb | |||||
| Total cholesterol, mmol/l | 5.82 (1.30) | 5.76 (1.22) | 5.77 (1.30) | 6.03 (1.32) | 5.95 (1.46) |
| HDL-cholesterol, mmol/l | 1.75 (0.40) | 1.76 (0.40) | 1.72 (0.32) | 1.67 (0.38) | 1.78 (0.45) |
| Triglycerides, mmol/l | 1.16 (0.76) | 1.11 (0.59) | 1.12 (0.53) | 1.35 (1.23) | 1.28 (1.14) |
| Lifestyle factorsb | |||||
| Moderate physical activity, % | 72.5 | 72.8 | 75.3 | 72.7 | 68.2 |
| Current smokers, % | 40.4 | 40.4 | 38.1 | 48.5 | 40.0 |
| Tumor characteristics | |||||
| Tumor size, mm | 24.6 (19.5) | 21.6 (18.6) | 26.1 (17.8) | 30.3 (19.1) | 29.2 (23.0) |
| Number of metastatic lymph nodes | 2.03 (3.92) | 1.46 (3.23) | 3.04 (4.66) | 2.00 (2.97) | 2.43 (4.67) |
| Stage, % | 1.77 (0.81) | 1.59 (0.68) | 1.92 (0.80) | 2.12 (0.96) | 1.95 (0.93) |
| 1 | 41.7 | 51.3 | 31.6 | 27.9 | 35.5 |
| 2 | 39.6 | 38.9 | 49.0 | 30.2 | 35.5 |
| 3 | 15.7 | 8.80 | 15.3 | 37.2 | 22.9 |
| 4 | 3.00 | 0.90 | 4.10 | 4.70 | 6.50 |
| Histologic grading, % | 1.92 (0.73) | 1.55 (0.57) | 2.13 (0.68) | 2.54 (0.51) | 2.49 (0.65) |
| 1 | 30.1 | 48.6 | 17.8 | 2.60 | 8.60 |
| 2 | 45.8 | 47.6 | 53.3 | 42.1 | 34.6 |
| 3 | 24.1 | 3.80 | 28.9 | 55.3 | 56.8 |
| Estrogen positive, % | 64.2 | 91.2 | 88.7 | 0 | 0 |
| Progesterone positive, % | 47.9 | 71.6 | 61.3 | 0 | 0 |
| HER2 positive, % | 16.0 | 0 | 34.0 | 100 | 0 |
| Ki-67% | 18.9 (17.3) | 8.43 (4.98) | 30.4 (16.1) | 27.9 (17.1) | 30.5 (22.0) |
| Treatment | |||||
| Type of surgery | |||||
| Breast conserving surgery | 45.6 | 54.5 | 45.1 | 33.0 | 27.0 |
| Mastectomy | 52.5 | 44.6 | 51.6 | 66.7 | 70.3 |
| Othersc | 1.90 | 0.90 | 3.30 | 0.30 | 2.70 |
| Chemotherapy, % | 38.2 | 25.9 | 52.6 | 51.5 | 49.4 |
| Radiation therapy, % | 48.6 | 66.8 | 67.0 | 39.4 | 54.1 |
| Endocrine therapy, % | 50.3 | 55.7 | 70.1 | 21.2 | 24.7 |
| Outcome | |||||
| Recurrence, % | 17.0 | 13.2 | 17.2 | 30.2 | 21.0 |
| Overall mortality, % | 27.8 | 19.7 | 29.3 | 39.5 | 40.4 |
| Breast cancer mortality, % | 14.4 | 5.27 | 20.2 | 27.9 | 24.5 |
aNumbers may vary due to missing information
bClinical variables, reproductive factors, serum samples, and lifestyle factors at study entry
cOther types of surgery include primary reconstruction and oncoplastic surgery
Abbreviations: BMI body mass index, HDL high density lipoprotein, HRT hormone replacement therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, n number of cases, SPB systolic blood pressure